Stifel downgraded FibroGen from Buy to Hold
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/8/2023 | $4.00 → $2.00 | Neutral → Underperform | BofA Securities |
| 6/26/2023 | Buy → Hold | Stifel | |
| 6/26/2023 | Buy → Neutral | BofA Securities | |
| 6/26/2023 | Outperform → Mkt Perform | Raymond James | |
| 6/26/2023 | Outperform → Mkt Perform | William Blair | |
| 6/2/2023 | $23.00 → $32.00 | Hold → Buy | Stifel |
| 1/31/2023 | Mkt Perform → Outperform | William Blair | |
| 1/26/2023 | $35.00 | Mkt Perform → Outperform | Raymond James |
10-Q - FIBROGEN INC (0000921299) (Filer)
8-K - FIBROGEN INC (0000921299) (Filer)
8-K - FIBROGEN INC (0000921299) (Filer)
Completed the sale of FibroGen China to AstraZeneca for approximately $220 millionInitiated the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC)Reached agreement with the U.S. Food and Drug Administration (FDA) on important design elements for the pivotal Phase 3 trial for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high red blood cell (RBC) transfusion burden Final protocol submission anticipated in 4Q 2025 Topline results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patie
SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce third quarter 2025 financial results on Monday, November 10 after market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by ph
FG-3246 Phase 2 dose optimization trial to enroll 75 patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-androgen receptor signaling inhibitor (ASRI) and pre-chemotherapy setting FG-3180 to be evaluated in the Phase 2 trial as a companion PET imaging agent and a potential predictive patient selection biomarker Interim analysis expected in 2H 2026 SAN FRANCISCO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the initiation of the Phase 2 monotherapy, dose-optimization trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46-expressing cancer lesions in patients with metastatic castration-r
4 - FIBROGEN INC (0000921299) (Issuer)
4 - FIBROGEN INC (0000921299) (Issuer)
4 - FIBROGEN INC (0000921299) (Issuer)
BofA Securities downgraded FibroGen from Neutral to Underperform and set a new price target of $2.00 from $4.00 previously
Stifel downgraded FibroGen from Buy to Hold
BofA Securities downgraded FibroGen from Buy to Neutral
4 - FIBROGEN INC (0000921299) (Issuer)
4 - FIBROGEN INC (0000921299) (Issuer)
4 - FIBROGEN INC (0000921299) (Issuer)
SAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025. "Michael is a well-recognized biotech industry veteran, who brings a wealth of biotech leadership experience to our board," said James Schoeneck, chairman of the board of directors of FibroGen. "His expertise spanning all stages of drug development will be invaluable as FibroGen progresses its pipeline. Michael's deep understanding of oncology will help the company through anticipated near-term clinical milestones and potential value-drivers." "FibroGen has differentiated potential first-in-class assets and
SAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The company previously announced that Juan Graham would step down on December 15, 2024. Reporting to Chief Executive Officer Thane Wettig, DeLucia will lead and oversee FibroGen's global finance organization. He has most recently served as FibroGen's Vice President, Head of Corporate Financial Planning and Analysis, Investor Relations, and Treasury. "Having worked closely with David for the past two and a half years, I am extremely confident he has the breadth and depth of experiences and capabili
SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities. The appointment is effective March 11, 2024. "Deyaa's leadership and expertise in oncology research and clinical development, particularly in bringing oncology therapeutics to market, will be key to accelerating our oncology pipeline and bringing novel cancer therapies to patients in need," said Thane Wettig, Chief Executive Officer of FibroGen. "We are excited to welcome him
Completed the sale of FibroGen China to AstraZeneca for approximately $220 millionInitiated the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC)Reached agreement with the U.S. Food and Drug Administration (FDA) on important design elements for the pivotal Phase 3 trial for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high red blood cell (RBC) transfusion burden Final protocol submission anticipated in 4Q 2025 Topline results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patie
SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce third quarter 2025 financial results on Monday, November 10 after market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by ph
Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $125 millionTransaction expected to close in 3Q 2025 Upon close of sale of FibroGen China, cash runway extended into 2028 Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), expected in 3Q 2025 Reached agreement with the U.S. Food and Drug Administration (FDA) on important design elements for a pivotal Phase 3 trial for roxadustat f
SC 13G/A - FIBROGEN INC (0000921299) (Subject)
SC 13G/A - FIBROGEN INC (0000921299) (Subject)
SC 13G/A - FIBROGEN INC (0000921299) (Subject)